- Advanced search
- Immuno Portal
- Malaria Portal
Compound class: Antibody
Comment: Vobarilizumab is an investigational bispecific peptide NanobodyTM which binds soluble IL-6R and human albumin (albumin binding being utilised as a half-life extension methodology). Design and production of ALX-0061 is described in patent US8748581 . Vobarilizumab is being developed for the treatment of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Preclinical information is published in .
The exact NanobodyTM structure being used as ALX-0061 was not revealed in the covering patent , but has been disclosed in the INN submission. Annotated peptide sequences for this therapeutic are available from its IMGT/mAb-DB record.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|No information available.|
|Summary of Clinical Use|
|Vobarilizumab (as research code ALX-0061) has reached Phase II clinical trial. See NCT02437890 (SLE) and NCT02518620 (RA) as examples.|
|Mechanism Of Action and Pharmacodynamic Effects|
|Interleukin-6 (IL-6) is a pleiotropic cytokine with a wide range of biological actions. IL-6 acts via its membrane-bound receptor (mIL-6R) in a classical interaction, or it can activate the soluble receptor (sIL-6R) in a process termed trans-signalling. IL-6 mediates inflammatory processes underlying many autoimmune diseases [1,3-5]. ALX-0061 appears to bind preferentially to the soluble receptor, and this is hypothesised to increase its clinical efficacy and reduce the adverse pharmacology associated with mIL-6R inhibition.|
|Clinical Trial ID||Title||Type||Source||Comment||References|
|NCT02437890||A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus||Phase 2 Interventional||Ablynx|
|NCT02518620||An Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of ALX-0061 in Subjects With Rheumatoid Arthritis||Phase 2 Interventional||Ablynx|